Guardant Health Q3 2026 Earnings Call - GUARDANT HEALTH INC

Explicit Guidance:

• FY2026 Revenue: Raised to $1.36–1.37 billion (approx. 38–40% YoY growth), up from prior guidance of $1.34–1.35 billion.
• FY2026 Oncology: Revenue growth expected at ~30% with volume growth >50%.
• FY2026 Biopharma & Data: Unchanged guidance for low double-digit revenue growth.
• FY2026 Screening: Revenue raised to $233–238 million; test volume expected at 285,000–290,000 tests (up from prior ~270,000).
• FY2026 Non-GAAP Gross Margin: Expected at 65%.
• FY2026 Non-GAAP Operating Expenses: Increased to $1.105–1.125 billion (22–24% YoY growth) to fund commercial expansion.
• FY2026 Free Cash Flow (FCF) Burn: Raised to $205–220 million (from $195–205 million).
  • Adjustment Note: $10–15 million of FCF shift from H2 2026 to H1 2027 due to CMS claims processing delays for the new Garden 360 Liquid CDX code; excluding this timing impact, FCF outlook is unchanged.
• Long-term FCF Targets: Company-wide FCF breakeven expected by end of 2027; Screening business standalone FCF breakeven expected by end of 2028.
• Shield Cost per Test: Target of $200 by end of 2028 (currently $330 in Q3 2026; floor expected at $700 ASP).

Business-Segment Outlook:

• Oncology (Therapy Selection & Monitoring):
  • Garden 360 Liquid: Volume growth expected ~30% for full year 2026; driven by "Smart Apps" and the new FDA-approved GARDEN260-CDX (ESR1 monitoring).
  • GARDEN260-CDX: FDA approved in September for AstraZeneca's ETCAMA; expects quarterly testing frequency (every 3 months) for ~37,000 HR-positive/HER2-negative breast cancer patients. Reimbursement via new PPA code expected H1 2027.
  • Garden 360 Tissue: PMA submitted; expects FDA approval in ~12 months (early 2027). Successful approval would open ADLT pathway.
  • Reveal (MRD):
    • Reveal Ultra: Clinical launch expected before year-end 2026; market-leading sensitivity (<1 ppm); significant growth opportunity for MRD.
    • Therapy Monitoring: "Tremendous volume growth" and increasing KOL adoption for tracking response earlier than imaging; potential to reach multi-million dollar testing opportunity in US.
    • Indication Expansion: COSMOS-MELO1 melanoma results published; MoVS submission for Melanoma expected in "coming months."
• Screening (SHIELD):
  • Volume: Growth driven by rep productivity and DTC campaigns; momentum expected to accelerate in 2027.
  • Coverage: ~100 million lives (80%+ of eligible US screening population) expected covered by end of 2026; significant tailwinds from UnitedHealthcare, Carillion, and Evicor decisions.
  • Infrastructure: New Palo Alto lab automation scheduled to go live in 2027 to drive further cost reductions.
  • MCD (Multi-Cancer Detection): SHIELD MCD receiving increasing physician opt-in; FDA Breakthrough Device designation secured; regulatory clearance pathway active.
• Biopharma & Data: Continued traction in companion diagnostics (31 cumulative approvals); "Infinity AI" decision support tools piloted.

Market and Competitive Outlook:

• Smart Apps: Launch of Wave 4 (11 new apps) next week; includes methylation signatures to predict therapy benefit (e.g., CERN benefit predictor) and PD-L1 detection for lung cancer immunotherapy selection. Dozens more features in development.
• Competitive Positioning:
  • Garden 360 CDX: Only FDA-approved companion diagnostic for ESR1-targeted therapies.
  • SHIELD: Positioned to lead multi-cancer detection via commercial reach, physician trust, and a "favorable regulatory pathway" (Breakthrough designation).
  • MRD: Reveal Ultra expected to set a higher performance bar; competitors' first-gen tests perceived as lacking sensitivity.
• Physician Adoption: Trend toward multiple tests per patient ("multiple tests at every fork in the road") rather than single lifetime profiling; increasing demand for blood-based PD-L1 and therapy switch decisions.

Macro / Industry Outlook:

• Economy/Politics: Management notes cancer care is a "bipartisan matter"; mid-term election results may impact oversight but no immediate changes to government affairs strategy anticipated.
• Reimbursement Environment:
  • CMS Delays: Temporary delay in claims processing for new Garden 360 Liquid CDX code (new billing code not recognized until January 2027).
  • NCD Updates: Working with CMS to update National Coverage Determination (NCD) to support quarterly testing frequency for ESR1 monitoring.
  • State Legislation: Momentum in state-level coverage expansion (e.g., Pennsylvania) due to USPSTF stagnation; other states expected to follow.
  • Payer Strategy: "Nobody wants to be first, nobody wants to be last"; favorable trends in commercial payer adoption observed.
• Regulatory: FDA Breakthrough designation for SHIELD MCD; ongoing reviews for Reveal breast MRD and immunotherapy monitoring.

Strategic Initiatives:

• Product Launches:
  • Wave 4 Smart Apps: Launching next week (Nov/Dec 2026); second largest launch in company history.
  • GARDEN260-CDX: Launched following FDA approval (Sept 2026) for ESR1 monitoring.
  • Reveal Ultra: Launched for biopharma partners; clinical launch to end of 2026.
  • SHIELD MCD: Data collection ongoing; regulatory submission path active.
• Capacity & Efficiency:
  • Lab Operations: Lower COGS/Shield workflow fully implemented Aug 2026 (cost down from $410 to $330).
  • New Lab: Palo Alto automation scheduled for 2027.
  • Commercial Expansion: Hiring additional rep class for early 2027; DTC investment increasing in 2027.
• R&D/Partnerships: Expanded partnerships with AstraZeneca; "Infinity AI" engine powering real-world evidence for biopharma partners.

Risks and Headwinds to Outlook:

• Reimbursement Timing: $10–15 million revenue recognition shift from H2 2026 to H1 2027 due to CMS system update delays for new CDX code.
• Payer Negotiations: Contracting with UnitedHealthcare and other commercial payers in early stages; ASPs may dip slightly (to ~$700 floor) as under-65 commercial mix increases before stabilizing.
• Regulatory Timelines: PMA approval for Garden 360 Tissue (~12 months); NCD updates for quarterly testing; Reveal Ultra reimbursement submissions.
• Seasonality: Potential slower summer patient flow; managed via improved rep productivity.
• Market Volatility: General market risks and uncertainties surrounding federal securities laws (standard disclaimer).

Management Tone on the Future:

• Confidence: "Very bullish" on future growth; "Early innings" of smart app and multi-disease screening stories.
• Sentiment: "More bullish than ever" regarding 2027 Shield growth; "Extremely pleased" with Reveal Ultra performance and therapy monitoring adoption.
• Hedges: Explicit acknowledgment of CMS timing impacts; caution on immediate material progress on commercial contracting (UnitedHealthcare); "Early days" for some new product launches.
• Execution: High confidence in "broad-based execution" across oncology and screening; strong rep productivity cited as a key differentiator.

Miscellaneous:

• Data Assets: >1.5 million patient tests run; >900,000 epigenetic profiles generated across 100+ tumor types powering "Infinity AI."
• Patient Impact: Case study highlighted of a 56-year-old colorectal cancer patient successfully monitored via Reveal to avoid ineffective chemo and confirm remission.
• Competitive Landscape: Notable shift toward blood-based testing for ESR1 monitoring and PD-L1 detection, reducing reliance on tissue for lung cancer biomarkers.